Background: Ataxia is caused by a variety of conditions leading to imbalance, incoordination and other disabilities. Current treatment is largely symptomatic. Ondansetron (a 5-HT3 antagonist) has been established as an anti-emetic in cancer patients, but has recently been shown to improve vertigo and cerebellar tremor in some patients.
Hypothesis: Ondansetron can improve symptoms of ataxia, imbalance and incoordination in four brain-injured patients.
Design: Placebo-controlled, double blind, crossover, 'n of 1' study, A-B-A design.
Subjects: Four patients with ataxia from traumatic brain injury.
Methods: Four patients underwent five separate tests of ataxia under three different conditions in a double blind fashion.
Results: For all subjects, there was little difference in scores in the five areas tested, with some improvement in tests of lower limb ataxia (10.4% for 4 mg and 10.7% for 8 mg ondansetron vs baseline).
Conclusion: Ondansetron use showed a trend towards improvement in tests of lower extremity ataxia but did not consistently improve scores in four patients.